4D Molecular Therapeutics Inc — Quarterly Cash Flow (NASDAQ:FDMT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Total assets 604.03 M560.38 M515.73 M473.64 M423.98 M Total liabilities 51.08 M49.78 M46.01 M52.75 M55 M Total equity 552.95 M510.61 M469.72 M420.89 M368.98 M Total liabilities & shareholders' equities 604.03 M560.38 M515.73 M473.64 M423.98 M Total debt ————— Net debt —————

News

4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:FDMT) 2026-01-19

RBC Capital reiterates Outperform rating on 4D Molecular stock at $32

Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock

4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT)

BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Aimei Health Technology (NASDAQ:AFJK), Aura Biosciences (NASDAQ:AURA)

Avago and Oracle among market cap stock movers on Wednesday

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript

4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential - Slideshow (NASDAQ:FDMT) 2025-12-17

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript

4d Molecular Therapeutics chief legal officer sells $17k in stock

4D Molecular Therapeutics appoints Kristian Humer as chief financial officer

4D Molecular Therapeutics stock price target raised by RBC to $32 on funding